Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
Status:
RECRUITING
Trial end date:
2033-12-30
Target enrollment:
Participant gender:
Summary
This trial is designed to investigate the safety, response rates and survival outcomes of patients with inoperable lung cancer by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through intra-tumor (IT).
Phase:
PHASE2
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University